RNXT Stock Price, RenovoRx, Inc. Quote, Chart

Market Summary

USD1.45+0.10

Market Closed

7.41%

RNXT Stock Price

View Fullscreen

RNXT RSI Chart

RNXT Valuation

Market Cap

32.3M

Price/Earnings (Trailing)

-4.02

Price/Free Cashflow

-3.31

RNXT Price/Earnings (Trailing)

RNXT Profitability

Return on Equity

-455.63%

Return on Assets

-168.15%

Free Cashflow Yield

-30.17%

RNXT Fundamentals

RNXT Earnings

Earnings (TTM)

-8.1M

Earnings Growth (Yr)

66.96%

Earnings Growth (Qtr)

66.66%

Breaking Down RNXT Revenue

52 Week Range

0.913.29

(Low)(High)

Last 7 days

6.3%

Last 30 days

14.4%

Last 90 days

-15.1%

Trailing 12 Months

-50.9%

How does RNXT drawdown profile look like?

RNXT Financial Health

Current Ratio

6.65

RNXT Investor Care

Shares Dilution (1Y)

136.40%

Diluted EPS (TTM)

-0.71

Tracking the Latest Insider Buys and Sells of RenovoRx, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Jan 26, 2024	spiegel robert j.	bought	-	-	40,983	-
Jan 26, 2024	marton laurence	bought	-	-	8,196	-
Jan 26, 2024	bagai shaun	bought	-	-	40,983	chief executive officer
Jan 26, 2024	agah ramtin	bought	-	-	40,983	chief medical officer
Jan 26, 2024	macfarlane k. angela	bought	-	-	40,983	-
Oct 03, 2023	nelms angela	bought	1,150	1.04634	1,100	chief operating officer
Nov 03, 2022	marton laurence	acquired	43,244	1.7	25,438	-
Jun 07, 2022	agah ramtin	bought	10,001	1.93	5,182	chief medical officer
May 19, 2022	bagai shaun	bought	11,275	2.05	5,500	chief executive officer
Mar 16, 2022	agah ramtin	gifted	-	-	975,000	chief medical officer

Which funds bought or sold RNXT recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 07, 2024	NIXON PEABODY TRUST CO	unchanged	-	-92,307	130,201	0.01%
May 01, 2024	CONCOURSE FINANCIAL GROUP SECURITIES, INC.	sold off	-	-	-	-%
Apr 12, 2024	Affinity Capital Advisors, LLC	unchanged	-	-12,615	17,794	-%
Mar 11, 2024	VANGUARD GROUP INC	reduced	-24.29	30,169	129,564	-%
Feb 14, 2024	STATE STREET CORP	unchanged	-	19,417	43,171	-%
Feb 14, 2024	BANK OF AMERICA CORP /DE/	new	-	270	270	-%
Feb 14, 2024	Royal Bank of Canada	new	-	-	-	-%
Feb 13, 2024	Tower Research Capital LLC (TRC)	added	108	7,594	10,532	-%
Feb 13, 2024	MORGAN STANLEY	sold off	-100	-234	-	-%
Feb 13, 2024	Ground Swell Capital, LLC	sold off	-100	-14,466	-	-%

Are Funds Buying or Selling RNXT?

Are funds buying RNXT calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own RNXT

No. of Funds

Unveiling RenovoRx, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2023	agah ramtin	-	152,872	SC 13G/A
Apr 14, 2022	bank of the west	10.79%	975,000	SC 13G
Feb 14, 2022	najmabadi kamran	11.7%	1,045,000	SC 13G
Feb 14, 2022	agah ramtin	-	1,089,948	SC 13G
Feb 10, 2022	boston scientific corp	106%	543,971	SC 13G

Recent SEC filings of RenovoRx, Inc.

View All Filings

Date Filed	Form Type	Document
May 10, 2024	10-Q	Quarterly Report
May 10, 2024	424B3	Prospectus Filed
May 10, 2024	424B3	Prospectus Filed
May 03, 2024	8-K	Current Report
Apr 30, 2024	DEF 14A	DEF 14A
Apr 26, 2024	S-3	S-3
Apr 22, 2024	D	D
Apr 19, 2024	S-3	S-3
Apr 18, 2024	8-K	Current Report
Apr 16, 2024	8-K	Current Report

Peers (Alternatives to RenovoRx, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	47.0B	6.8B	9.93%	-6.23%	-7.88	6.87	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	19.2B	2.0B	-2.86%	-28.22%	-57.69	9.56	75.20%	68.82%
BMRN	15.5B	2.5B	-8.14%	-14.08%	75.54	6.28	13.74%	186.89%
INCY	12.0B	3.8B	-3.24%	-16.29%	16.12	3.19	8.58%	129.81%
MID-CAP
BBIO	5.4B	107.9M	1.09%	107.81%	-9.83	48.09	54.84%	-28.31%
APLS	5.2B	524.1M	-22.77%	-53.41%	-12.37	9.85	394.93%	39.61%
AXSM	3.5B	251.0M	1.40%	-8.18%	-11.81	13.94	73.58%	-86.73%
ARWR	3.1B	240.7M	-5.68%	-38.85%	-6.52	12.77	-1.03%	-213.43%
ACAD	2.5B	813.8M	-16.31%	-29.84%	-1.5K	3.09	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	-0.76%	-10.51%	28.42	4.5	60.38%	-34.49%
NVAX	627.6M	996.6M	1.36%	-50.17%	-1.57	0.63	-26.66%	65.49%
CRBP	467.5M	881.7K	16.76%	369.92%	-13.85	481.06	-77.61%	33.36%
INO	260.8M	4.9M	-4.04%	14.81%	-1.93	53.59	-54.97%	51.71%
IBIO	6.4M	2.1M	-14.75%	74.53%	-0.24	2.14	-13.45%	66.37%

RenovoRx, Inc. News

Latest updates

RenovoRx, Inc. Earnings Report: Key Takeaways & Analysis

Balance Sheet

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Balance Sheet												(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2020Q4
Assets	226.6%	4,788	1,466	3,519	6,314	4,561	7,265	9,250	11,243	13,946	16,287	18,178	1,914
Current Assets	-	-	-	-	-	-	7,265	9,250	11,243	13,943	16,281	18,164	1,910
Cash Equivalents	265.8%	4,389	1,200	3,200	6,000	3,700	4,391	3,093	2,769	13,121	15,192	17,725	1,795
Liabilities	-32.4%	3,021	4,466	3,513	5,126	1,305	1,102	1,102	1,123	1,406	938	625	4,119
Current Liabilities	-7.0%	1,093	1,175	1,605	1,699	-	1,102	-	-	-	938	625	4,096
Shareholder's Equity	158.9%	1,767	-3,000	6.00	1,188	3,256	6,163	8,148	10,120	12,540	15,349	17,553	-
Retained Earnings	-2.6%	-42,481	-41,400	-38,200	-36,800	-34,430	-31,173	-29,017	-26,881	-24,300	-21,284	-18,900	-14,960
Additional Paid-In Capital	15.2%	44,246	38,404	38,183	37,944	37,685	37,318	37,151	37,004	36,826	36,632	36,481	303
Shares Outstanding	57.7%	16,866	10,694	10,693	10,693	9,131	9,098	9,039	9,025	8,992	8,934	5,620	2,233
Float	-	-	-	-	15,500	-	-	-	15,500	-	-	-	-

Cashflow (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)															(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3
Cashflow From Operations	-7.4%	-2,204	-2,053	-2,728	-2,771	-2,706	-1,681	-2,672	-2,361	-2,097	-2,558	-1,119	-1,247	-992	-	-
Share Based Compensation	91.4%	423	221	239	257	361	164	143	169	168	126	6.00	7.00	8.00	-	7.00
Cashflow From Investing	-	-	-	-	-	2,032	2,976	2,992	-	-	-	-	-	-	-	-
Cashflow From Financing	-	5,420	-	-	5,002	6.00	3.00	4.00	9.00	26.00	25.00	17,287	1,982	34.00	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

RNXT Income Statement

2023-12-31

Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Operating expenses:
Research and development	$ 5,667	$ 4,301
General and administrative	5,729	5,649
Total operating expenses	11,396	9,950
Loss from operations	(11,396)	(9,950)
Change in fair value of warrant liability	1,709
Interest income (expense), net	108	57
Other income, net		4
Financing costs allocated to warrant	(653)
Total other income (expenses), net	1,164	61
Net loss	(10,232)	(9,889)
Other comprehensive income:
Unrealized gain on marketable securities		17
Comprehensive loss	$ (10,232)	$ (9,872)
Net loss per share, basic	$ (0.99)	$ (1.09)
Net loss per share, diluted	$ (0.99)	$ (1.09)
Weighted-average shares of common stock outstanding, basic	10,290,667	9,051,726
Weighted-average shares of common stock outstanding, diluted	10,290,667	9,051,726

RNXT Balance Sheet

2023-12-31

Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 1,173	$ 4,391
Short-term marketable securities		2,049
Prepaid expenses and other current assets	192	825
Deferred offering costs	101
Total assets	1,466	7,265
Current liabilities:
Accounts payable	561	534
Accrued expenses	614	568
Total current liabilities	1,175	1,102
Common stock warrant liability	3,291
Total liabilities	4,466	1,102
Commitments and contingencies (Note 6)
Convertible preferred stock and stockholders’ equity (deficit):
Convertible preferred stock, $0.0001 par value; 15,000,000 shares authorized as of December 31, 2023 and 2022, respectively; zero shares issued and outstanding at December 31, 2023 and 2022, respectively
Common stock, $0.0001 par value, 250,000,000 shares authorized at December 31, 2023, and 2022, respectively; 10,693,580 and 9,097,701 shares issued and outstanding as of December 31, 2023, and 2022, respectively	1	1
Additional paid-in capital	38,404	37,318
Accumulated other comprehensive income		17
Accumulated deficit	(41,405)	(31,173)
Total convertible preferred stock and stockholders’ (deficit) equity	(3,000)	6,163
Total liabilities, convertible preferred stock and stockholders’ equity (deficit)	$ 1,466	$ 7,265

About RenovoRx, Inc.

RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid tumors. Its lead product candidate is RenovoGem, a drug and device combination consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. The company has a research collaboration with Imugene Limited to deliver oncolytic virus therapy for the treatment of difficult-to-access tumors. The company was founded in 2009 and is headquartered in Los Altos, California.

CEO	Mr. Shaun R. Bagai
WEBSITE	https://renovorx.com
INDUSTRY	Biotechnology
EMPLOYEES	10

RenovoRx, Inc. Frequently Asked Questions

What is the ticker symbol for RenovoRx, Inc.? What does RNXT stand for in stocks?

RNXT is the stock ticker symbol of RenovoRx, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of RenovoRx, Inc. (RNXT)?

As of Thu May 09 2024, market cap of RenovoRx, Inc. is 22.77 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of RNXT stock?

You can check RNXT's fair value in chart for subscribers.

What is the fair value of RNXT stock?

You can check RNXT's fair value in chart for subscribers. The fair value of RenovoRx, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of RenovoRx, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for RNXT so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is RenovoRx, Inc. a good stock to buy?

The fair value guage provides a quick view whether RNXT is over valued or under valued. Whether RenovoRx, Inc. is cheap or expensive depends on the assumptions which impact RenovoRx, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for RNXT.